In-house production facility underpins broad CAR T pipeline
Over the past decade, Celyad Oncology has established expertise in Good Manufacturing Practice (GMP) grade cell therapy manufacturing at our 11,000 sq. ft. in-house facility, which is equipped to support our ongoing clinical trials. The manufacturing facility has been instrumental over the past few years in implementing multiple chemistry, manufacturing, and control (CMC) amendments associated with our CAR T programs, including our proprietary OptimAb manufacturing process for our autologous acute myeloid leukemia franchise.
The facility offers the flexibility to manufacture both our allogeneic and autologous CAR T programs. In addition, leveraging our All-in-One Vector approach for CAR T production has helped streamline the manufacturing process of our candidates.
Celyad Oncology’s manufacturing facility, located in Mont-Saint-Guibert, Belgium, provides the capability to manufacture multiple CAR T products including both our allogeneic and autologous candidates